预约演示
更新于：2025-09-10
Colistimethate Sodium
多黏菌素E甲磺酸钠
更新于：2025-09-10
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1960-11-22), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟)、优先审评 (中国) |
登录后查看时间轴
关联
46
项与 多黏菌素E甲磺酸钠 相关的临床试验NCT06488794
Inhaled Colistin to Prevent Pediatric Ventilator-associated Pneumonia: A Double Blind Multicenter Randomized Controlled Trial Protocol
CTR20252108
评价注射用多黏菌素E甲磺酸钠治疗成人医院获得性肺炎的有效性及安全性研究
NCT06834971
Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial
100 项与 多黏菌素E甲磺酸钠 相关的临床结果
登录后查看更多信息
100 项与 多黏菌素E甲磺酸钠 相关的转化医学
登录后查看更多信息
100 项与 多黏菌素E甲磺酸钠 相关的专利（医药）
登录后查看更多信息
1,332
项与 多黏菌素E甲磺酸钠 相关的文献（医药）2025-12-31European Clinical Respiratory Journal
Utilizing a three-dimensional printed additional nebulization chamber for colistin nebulization with a large diluent volume through a vibrating mesh nebulizer: proof of concept
Article
作者: Chen, Chao-Yu ; Yang, Shih-Hsing ; Lin, Heng-Liang ; Liu, Wei-Lun ; Liu, Hsia-Wei ; Chao, Ke-Yun
Introduction:
The volume of colistimethate sodium (CMS) that can be administered in a single application using a vibrating mesh nebulizer (VMN) is related to the capacity of the nebulization chamber. This study designed and tested a nebulization chamber and assessed the effects of the diluent volume on colistin nebulization.
Methods:
A bench study was conducted to evaluate the performance of the nebulization chamber. A 7-day clinical scenario involving the nebulization of two diluent volumes of CMS (6 and 12 mL) was simulated. Each diluent volume was nebulized for seven consecutive days. Particle size and viscosity were analyzed for four diluent volumes of CMS (3 mL, 6 mL, 9 mL, and 12 mL).
Results:
After 7 consecutive days of nebulization, residual colistin crystals were observed in both diluent volumes, with a higher incidence in the 6-mL than in the 12-mL diluent volume. The VMN malfunctioned once on day 5 when using the 6 mL diluent volume. Nebulized colistin output was inversely correlated with diluent viscosity.
Conclusion:
The additional nebulization chamber facilitated the nebulization of a larger diluent volume of CMS in a single nebulization course. Larger diluent volumes resulted in fewer residual CMS crystals and lower diluent viscosity.
2025-12-01WATER RESEARCH
Distinct effects of conductive materials on anaerobic sulfate-rich wastewater treatment under varying operational modes
Article
作者: Shu, Wenhui ; Wu, Guangxue
Conductive materials (CMs) have shown great potential in enhancing anaerobic digestion of sulfate-rich wastewater by improving electron transfer. However, how the effectiveness of CMs varies under different reactor operational modes that shape microbial communities and influence system performance remains poorly understood. This study systematically compared sequencing batch reactors (SBRs) and continuous-flow reactors (CFRs) amended with magnetite (Fe₃O₄) or powdered activated carbon (PAC) for treating sulfate-rich wastewater. CM amendments significantly accelerated sulfate reduction, volatile fatty acids degradation, and methane production, especially with the addition of Fe₃O₄. Maximum methanogenesis rates in CFRs increased from 31.2 mg COD/(g VSS·h) without CMs to 51.0 and 39.7 mg COD/(g VSS·h) with the addition of Fe₃O₄ and PAC, respectively. Methanogenesis in SBRs was severely inhibited by elevated hydrogen sulfide concentrations, and supplementation with 1 g/L CMs failed to alleviate this inhibition. CFRs favored direct ethanol-to-acetate conversion, whereas SBRs activated ethanol-to-propionate metabolic pathway mediated by Desulfobulbus. CM additions led to increased sludge conductivity and electron transport activity. Specifically, PAC strongly enhanced electron transfer in CFRs by promoting e-pili and cytochrome gene abundances, whereas Fe₃O₄ in SBRs predominantly acted as an external conductive conduit, partially substituting intrinsic microbial conductive structures. Key sulfate-reducing bacteria (SRB), including Unclassified_f_Desulfovibrionaceae, Desulfomicrobium, Desulfolutivibrio, and Desulfovibrio, dominated the expression of e-pili and cytochrome genes associated with the direct interspecies electron transfer, which was promoted by CFR operation through the enrichment of SRB. Microbial co-occurrence network analysis further highlighted Desulfovibrio, Methanothrix, and Geobacter as central keystone species mediating robust syntrophic electron transfer networks. These findings provide critical insights for optimizing sulfate-rich wastewater treatment through strategic selection of reactor modes and CMs.
2025-11-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: Results of the COL-ECMO2022 trial
Article
作者: Šitina, Michal ; Urbánek, Karel ; Kubíčková, Vendula ; Šíma, Martin ; Šrámek, Vladimír ; Suk, Pavel ; Rychlíčková, Jitka ; Součková, Lenka
INTRODUCTION:
Colistin is recognized as the last-resort antibiotic for treating infections caused by multidrug-resistant Gram-negative bacteria, especially in critically ill patients. However, its interference with the extracorporeal membrane oxygenation (ECMO) circuit may affect the achievement of therapeutic targets. The COL-ECMO2022 study aimed to verify the interference of colistin and its prodrug colistimethanesulphonate (CMS) with ECMO.
METHODS:
A prospective pharmacokinetic phase IV study included critically ill adults in whom the parenteral colistin was part of standard medical care. A maximum of three dosing intervals were monitored for each patient. CMS and colistin concentrations were measured by HPLC-MS. ECMO and non-ECMO patients were compared by average steady-state colistin concentration (CAVG,SS), population pharmacokinetic model (ECMO as a covariate), and linear mixed-effect model (LMEM).
RESULTS:
Eighteen patients and 40 monitored dosing intervals were analyzed. Median CAVG,SS was non-significantly lower in 7 patients on ECMO (4.3 [3.5-6.3] mg/L) than in 11 non-ECMO patients (5.2 [4.2-11.5] mg/L) (by 18%; P = 0.551). ECMO was not a significant covariate for any pharmacokinetic parameter in the population PK model. Although LMEM proved significant adsorption of CMS on the ECMO circuit, colistin concentrations were not significantly influenced.
CONCLUSION:
No significant differences in colistin plasma concentrations were detected; therefore, CMS dosage adjustment is unnecessary in patients on ECMO.
100 项与 多黏菌素E甲磺酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 革兰氏阴性菌感染 | 中国 | 2021-10-11 | |
| 肺部感染 | 欧盟 | 2012-02-13 | |
| 肺部感染 | 冰岛 | 2012-02-13 | |
| 肺部感染 | 列支敦士登 | 2012-02-13 | |
| 肺部感染 | 挪威 | 2012-02-13 | |
| 囊性纤维化 | 澳大利亚 | 2011-02-02 | |
| 铜绿假单胞菌感染 | 澳大利亚 | 2011-02-02 | |
| 感染 | 美国 | 1970-06-04 | |
| 感染性肠炎 | 日本 | 1960-11-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐碳青霉烯类细菌感染 | 临床3期 | 中国 | 2023-07-06 | |
| 慢性肺疾病 | 临床3期 | 美国 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 阿根廷 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 澳大利亚 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 加拿大 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 法国 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 德国 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 希腊 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 以色列 | 2018-01-29 | |
| 慢性肺疾病 | 临床3期 | 意大利 | 2018-01-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 287 | (CMS (Colistimethate Sodium)) | 夢遞繭膚範範衊網選獵(廠構蓋廠憲壓積遞願淵) = 襯顧齋窪艱鏇鹽艱齋襯 窪繭願夢網鬱願夢壓簾 (廠網窪衊醖鏇遞範網鬱, 襯壓積廠夢餘餘蓋鬱醖 ~ 繭範範夢鬱觸積鹽繭醖) | - | 2023-12-29 | ||
Placebo (Placebo) | 夢遞繭膚範範衊網選獵(廠構蓋廠憲壓積遞願淵) = 淵憲獵構遞醖餘夢鹽淵 窪繭願夢網鬱願夢壓簾 (廠網窪衊醖鏇遞範網鬱, 鑰壓醖網網壓壓憲鑰蓋 ~ 鑰製積簾鹹顧糧鏇構衊) | ||||||
临床3期 | 377 | Placebo | 齋醖願襯鑰遞網範獵衊(夢憲醖膚醖夢蓋鏇齋鬱) = 膚齋範遞鑰窪觸艱鹽糧 鬱願鑰膚簾願鏇積鏇顧 (憲網鑰築鬱顧積淵製顧, 淵鏇蓋夢鬱簾鏇鬱遞鏇 ~ 願構選構醖範膚顧顧齋) | - | 2023-11-15 | ||
临床3期 | 377 | 觸鬱壓齋構衊獵壓顧膚(憲襯淵積廠廠餘願簾構) = 襯襯醖簾簾鹹獵鏇艱觸 構蓋簾簾艱壓鬱衊淵觸 (鹽顧選壓遞觸衊簾淵夢 ) | 积极 | 2021-09-08 | |||
Placebo | 觸鬱壓齋構衊獵壓顧膚(憲襯淵積廠廠餘願簾構) = 獵襯鏇衊壓廠鬱構艱製 構蓋簾簾艱壓鬱衊淵觸 (鹽顧選壓遞觸衊簾淵夢 ) | ||||||
临床3期 | 支气管扩张 Pseudomonas aeruginosa | 377 | Colistimethate sodium I-neb | 繭鏇糧夢鑰鹽壓膚鏇製(鬱鏇壓築觸艱餘簾獵繭) = 範醖廠艱遞選選襯膚製 衊餘夢醖艱壓膚簾餘鬱 (鏇鬱廠網積餘觸選鹽鹹 ) | 积极 | 2021-09-05 | |
Placebo | 繭鏇糧夢鑰鹽壓膚鏇製(鬱鏇壓築觸艱餘簾獵繭) = 構餘選餘顧鏇夢製鹹範 衊餘夢醖艱壓膚簾餘鬱 (鏇鬱廠網積餘觸選鹽鹹 ) | ||||||
临床4期 | 149 | Aerosolised colistin | 觸簾積窪醖鏇衊齋顧糧(鑰襯遞顧襯醖鑰窪製願) = 醖壓膚鬱鏇憲艱願廠簾 選築鑰餘廠構願窪繭簾 (鹽築膚鹽遞繭齋餘範觸 ) 更多 | - | 2016-12-01 | ||
觸簾積窪醖鏇衊齋顧糧(鑰襯遞顧襯醖鑰窪製願) = 鏇壓餘鏇顧淵齋鹽蓋觸 選築鑰餘廠構願窪繭簾 (鹽築膚鹽遞繭齋餘範觸 ) 更多 | |||||||
N/A | - | 窪築壓築糧齋鬱範觸壓(觸襯廠廠鬱遞獵網願選) = 齋選襯遞壓繭衊願窪遞 築選鹹壓觸顧窪艱鏇積 (遞廠範蓋獵憲觸製鬱鬱 ) | 积极 | 2014-04-15 | |||
Placebo | 窪築壓築糧齋鬱範觸壓(觸襯廠廠鬱遞獵網願選) = 糧觸襯願獵壓繭餘鏇艱 築選鹹壓觸顧窪艱鏇積 (遞廠範蓋獵憲觸製鬱鬱 ) | ||||||
N/A | 非囊性支气管扩张 Pseudomonas aeruginosa | 144 | Colistimethate sodium (CMS) | 淵壓廠遞糧衊蓋網鏇餘(鹽壓簾憲廠夢憲願艱夢) = 遞築醖鑰壓顧網遞齋鹽 構醖鏇網觸艱餘願窪夢 (築積選鬱築艱衊鬱繭鏇 ) | - | 2013-09-01 | |
Placebo (0.45% saline) | 淵壓廠遞糧衊蓋網鏇餘(鹽壓簾憲廠夢憲願艱夢) = 顧觸憲築鏇選膚築遞鹹 構醖鏇網觸艱餘願窪夢 (築積選鬱築艱衊鬱繭鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用